Nicotinic receptors in aging and dementia

Journal of Neurobiology

Volumn 53, Issue 4, 2002, Pages 641-655

  Picciotto, Marina R ^a   Zoli, Michele ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Acetylcholine; Alzheimer's disease; nAChR; Neuroprotection; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ACETYLCHOLINE; ALCOHOL; AMYLOID BETA PROTEIN; ARACHIDONIC ACID; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CALCIUM BINDING PROTEIN; CASPASE 3; CASPASE 8; CASPASE 9; CHOLINERGIC RECEPTOR; CYTOCHROME C; FIBROBLAST GROWTH FACTOR 2; GLUTAMIC ACID; IBOTENIC ACID; KAINIC ACID; LACTATE DEHYDROGENASE; N METHYL DEXTRO ASPARTIC ACID; NERVE GROWTH FACTOR RECEPTOR; NEUROTOXIN; NEUROTROPHIC FACTOR; NICOTINE; NICOTINIC AGENT; NICOTINIC RECEPTOR; NITRIC OXIDE SYNTHASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); UNINDEXED DRUG;

AGING; ARTICLE; CHOLINERGIC ACTIVITY; COGNITION; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DEMENTIA; DRUG RECEPTOR BINDING; HUMAN; HYPOTHESIS; MEDICAL LITERATURE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; SMOKING;

AGING; ANIMALS; BRAIN; COGNITION; DEMENTIA; HUMANS; NEUROPROTECTIVE AGENTS; NICOTINE; RECEPTORS, NICOTINIC; SMOKING;

EID: 0036890784     PISSN: 00223034     EISSN: None     Source Type: Journal    
DOI: 10.1002/neu.10102     Document Type: Article

References (144)

1. Abrous DN, Adriani W, Montaron M-F, Aurousseau C, Rougon G, Le Moal M, Piazza PV. 2002. Nicotine self-administration impairs hippocampal plasticity. J Neurosci 22:3656-3662.
2. Acri JB, Brown KJ, Saah MI, Grunberg NE. 1995. Strain and age differences in acoustic startle responses and effects of nicotine in rats. Pharmacol Biochem Behav 50:191-198.
3. Akaike A, Tamura Y, Yokota T, Shimohama S, Kimura J. 1994. Nicotine-induced protection of cultured cortical neurons against N-methyl-D-aspartate receptor-mediated glutamate cytotoxicity. Brain Res 644:181-187.
4. Almeida OP, Hulse GK, Lawrence D, Flicker L. 2002. Smoking as a risk factor for Alzheimer's disease: Contrasting evidence from a systematic review of case-control and cohort studies. [Review] [49 refs]. Addiction 97:15-28.
5. Araujo DM, Lapchak PA, Meaney MJ, Collier B, Quirion R. 1990. Effects of aging on nicotinic and muscarinic autoreceptor function in the rat brain: Relationship to presynaptic cholinergic markers and binding sites. J Neurosci 10:3069-3078.
6. Arendash GW, Sanberg PR, Sengstock GJ. 1995a. Nicotine enhances the learning and memory of aged rats. Pharmacol Biochem Behav 52:517-523.
7. Arendash GW, Sengstock GJ, Sanberg PR, Kem WR. 1995b. Improved learning and memory in aged rats with chronic administration of the nicotinic receptor agonist GTS-21. Brain Res 674:252-259.
8. Aubert I, Araujo DM, Cécyre D, Robitaille Y, Gauthier S, Quirion R. 1992. Comparative alteration of nicotinic and muscarinic binding sites in Alzheimer's and Parkinson's diseases. J Neurochem 58:529-541.
9. Auld DS, Kar S, Quirion R. 1998. Beta-amyloid peptides as direct cholinergic neuromodulators: A missing link? Trends Neurosci 21:43-49.
10. Bartus RT, Dean RLd, Beer B, Lippa AS. 1982. The cholinergic hypothesis of geriatric memory dysfunction. Science 217:408-414.
11. Behmand RA, Harik SI. 1992. Nicotine enhances 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. J Neurochem 58:776-779.
12. Belluardo N, Blum M, Mudo G, Andbjer B, Fuxe K. 1998. Acute intermittent nicotine treatment produces regional increases of basic fibroblast growth factor messenger RNA and protein in the tel- and diencephalon of the rat. Neuroscience 83:723-740.
13. Belluardo N, Mudo G, Blum M, Cheng Q, Caniglia G, Dell'Albani P, Fuxe K. 1999a. The nicotinic acetylcholine receptor agonist (=)-epibatidine increases FGF-2 mRNA and protein levels in the rat brain. Mol Brain Res 74:98-110.
14. Belluardo N, Mudo G, Caniglia G, Cheng Q, Blum M, Fuxe K. 1999b. The nicotinic acetylcholine receptor agonist ABT-594 increases FGF-2 expression in various rat brain regions. NeuroReport 10:3909-3913.
15. Berger F, Gage FH, Vijayaraghavan S. 1998. Nicotinic receptor-induced apoptotic cell death of hippocampal progenitor cells. J Neurosci 18:6871-6881.
16. Birtsch C, Wevers A, Traber J, Maelicke A, Bloch W, Schroder H. 1997. Expression of alpha 4-1 and alpha 5 nicotinic cholinoceptor mRNA in the aging rat cerebral cortex. Neurobiol Aging 18:335-342.
17. Blum M, Wu G, Mudo G, Belluardo N, Andersson K, Agnati LF, Fuxe K. 1996. Chronic continuous infusion of (-)nicotine reduces basic fibroblast growth factor messenger RNA levels in the ventral midbrain of the intact but not of the 6-hydroxydopamine-lesioned rat. Neuroscience 70:169-177.
18. Borlongan CV, Shytle RD, Ross SD, Shimizu T, Freeman TB, Cahill DW, Sanberg PR. 1995. Nicotine protects against systemic kainic acid-induced excitotoxic effects. Exp Neurol 136:261-265.
19. Breitner JC. 1996. The role of anti-inflammatory drugs in the prevention and treatment of Alzheimer's disease. Annu Rev Med 47:401-411.
20. Buccafusco JJ, Jackson WJ. 1991. Beneficial effects of nicotine administered prior to a delayed matching-to-sample task in young and aged monkeys. Neurobiol Aging 12:233-238.
21. Buccafusco JJ, Jackson WJ, Jonnala RR, Terry Jr AV. 1999. Differential improvement in memory-related task performance with nicotine by aged male and female rhesus monkeys. Behav Pharmacol 10:681-690.
22. Caldarone BJ, Duman CH, Picciotto MR. 2000. Fear conditioning and latent inhibition in mice lacking the high affinity subclass of nicotinic acetylcholine receptors in the brain. Neuropharmacology 39:2779-2784.
23. Carlson J, Noguchi K, Ellison G. 2001. Nicotine produces selective degeneration in the medial habenula and fasciculus retroflexus. Brain Res 906:127-134.
24. Carlson NG, Bacchi A, Rogers SW, Gahring LC. 1998. Nicotine blocks TNF-alpha-mediated neuroprotection to NMDA by an alpha-bungarotoxin-sensitive pathway. J Neurobiol 35:29-36.
25. Carr LA, Basham JK. 1991. Effects of tobacco smoke constituents on MPTP-induced toxicity and monoamine oxidase activity in the mouse brain. Life Sci 48:1173-1177.
26. Cormier A, Morin C, Zini R, Tillement JP, Lagrue G. 2001. In vitro effects of nicotine on mitochondrial respiration and superoxide anion generation. Brain Res 900:72-79.
27. Costa G, Abin-Carriquiry JA, Dajas F. 2001. Nicotine prevents striatal dopamine loss produced by 6-hydroxydopamine lesion in the substantia nigra. Brain Res 888:336-342.
28. Court JA, Lloyd S, Johnson M, Griffiths M, Birdsall NJ, Piggott MA, Oakley AE, Ince PG, Perry EK, Perry RH. 1997. Nicotinic and muscarinic cholinergic receptor binding in the human hippocampal formation during development and aging. Dev Brain Res 101:93-105.
29. Cucina A, Corvino V, Sapienza P, Borrelli V, Lucarelli M, Scarpa S, Strom R, Santoro-D'Angelo L, Cavallaro A. 1999. Nicotine regulates basic fibroblastic growth factor and transforming growth factor betal production in endothelial cells. Biochem Biophys Res Commun 257:306-312.
30. Dajas-Bailador FA, Lima PA, Wonnacott S. 2000. The alpha7 nicotinic acetylcholine receptor subtype mediates nicotine protection against NMDA excitotoxicity in primary hippocampal cultures through a Ca(2+) dependent mechanism. Neuropharmacology 39:2799-2807.
31. Decker MW. 1987. The effects of aging on hippocampal and cortical projections of the forebrain cholinergic system. Brain Res 434:423-438.
32. Dineley KT, Westerman M, Bui D, Bell K, Ashe KH, Sweatt JD. 2001. Beta-amyloid activates the mitogen-activated protein kinase cascade via hippocampal alpha7 nicotinic acetylcholine receptors: In vitro and in vivo mechanisms related to Alzheimer's disease. J Neurosci 21:4125-4133.
33. Donnelly-Roberts DL, Xue IC, Arneric SP, Sullivan JP. 1996. In vitro neuroprotective properties of the novel cholinergic channel activator (ChCA), ABT-418. Brain Res 719:36-44.
34. Efthimiopoulos S, Vassilacopoulou D, Ripellino JA, Tezapsidis N, Robakis NK. 1996. Cholinergic agonists stimulate secretion of soluble full-length amyloid precursor protein in neuroendocrine cells. Proc Natl Acad Sci USA 93:8046-8050.
35. Elbaz A, Manubens-Bertran JM, Baldereschi M, Breteler MM, Grigoletto F, Lopez-Pousa S, Dartigues JF, Alperovitch A, Rocca WA, Tzourio C. 2000. Parkinson's disease, smoking, and family history. EUROPARKINSON Study Group. J Neurol 247:793-798.
36. Engstrom DA, Bickford P, De La Garza R, Young D, Rose GM. 1993. Increased responsiveness of hippocampal pyramidal neurons to nicotine in aged, learning-impaired rats. Neurobiol Aging 14:259-266.
37. Ferger B, Spratt C, Earl CD, Teismann P, Oertel WH, Kuschinsky K. 1998. Effects of nicotine on hydroxyl free radical formation in vitro and on MPTP-induced neurotoxicity in vivo. Naunyn Schm Arch Pharmacol 358:351-359.
38. Ferrari R, Frasoldati A, Leo G, Torri C, Zini I, Agnati LF, Zoli M. 1999. Changes in nicotinic acetylcholine receptor subunit mRNAs and nicotinic binding in spontaneously hypertensive stroke prone rats. Neurosci Lett 277:169-172.
39. Fratiglioni L, Wang HX. 2000. Smoking and Parkinson's and Alzheimer's disease: Review of the epidemiological studies. Beh Brain Res 113:117-120.
40. French SJ, Humby T, Horner CH, Sofroniew MV, Rattray M. 1999. Hippocampal neurotrophin and trk receptor mRNA levels are altered by local administration of nicotine, carbachol and pilocarpine. Mol Brain Res 67:124-136.
41. Fujii S, Sumikawa K. 2001. Acute and chronic nicotine exposure reverse age-related declines in the induction of long-term potentiation in the rat hippocampus. Brain Res 894:347-353.
42. Fuxe K, Janson AM, Jansson A, Andersson K, Eneroth P, Agnati LF. 1990. Chronic nicotine treatment increases dopamine levels and reduces dopamine utilization in substantia nigra and in surviving forebrain dopamine nerve terminal systems after a partial di-mesencephalic hemitransection. Naunyn-Schm Arch Pharmacol 341:171-181.
43. Fuxe K, Rosen L, Lippoldt A, Andbjer B, Hasselrot U, Finnman UB, Agnati LF. 1994. Chronic continuous infusion of nicotine increases the disappearance of choline acetyltransferase immunoreactivity in the cholinergic cell bodies of the medial septal nucleus following a partial unilateral transection of the fimbria fornix. Clin Invest 72:262-268.
44. Garrido R, Malecki A, Hennig B, Toborek M. 2000. Nicotine attenuates arachidonic acid-induced neurotoxicity in cultured spinal cord neurons. Brain Res 861:59-68.
45. Garrido R, Mattson MP, Hennig B, Toborek M. 2001. Nicotine protects against arachidonic-acid-induced caspase activation, cytochrome c release and apoptosis of cultured spinal cord neurons. J Neurochem 76:1395-1403.
46. Gioanni Y, Rougeot C, Clarke PBS, Lepouse C, Thierry AM, Vidal C. 1999. Nicotinic receptors in the rat prefrontal cortex: Increase in glutamate release and facilitation of mediodorsal thalamo-cortical transmission. Eur J Neurosci 11:18-30.
47. Gotti C, Carbonnelle E, Moretti M, Zwart R, Clementi F. 2000. Drugs selective for nicotinic receptor subtypes: A real possibility or a dream? Beh Brain Res 113:183-192.
48. Gotti C, Fornasari D, Clementi F. 1997. Human neuronal nicotinic receptors. Prog Neurobiol 53:199-237.
49. Grilly DM, Simon BB, Levin ED. 2000. Nicotine enhances stimulus detection performance of middle- and old-aged rats: A longitudinal study. Pharmacol Biochem Behav 65:665-670.
50. Guan ZZ, Zhang X, Ravid R, Nordberg A. 2000. Decreased protein levels of nicotinic receptor subunits in the hippocampus and temporal cortex of patients with Alzheimer's disease. J Neurochem 74:237-243.
51. Guan ZZ, Miao H, Tian JY, Unger C, Nordberg A, Zhang X. 2001. Suppressed expression of nicotinic acetylcholine receptors by nanomolar beta-amyloid peptides in PC12 cells. J Neural Trans 108:1417-1433.
52. Hadjiconstantinou M, Hubble JP, Wemlinger TA, Neff NH. 1994. Enhanced MPTP neurotoxicity after treatment with isoflurophate or cholinergic agonists. J Pharmacol Exp Therap 270:639-644.
53. Hellstrom-Lindahl E. 2000. Modulation of beta-amyloid precursor protein processing and tau phosphorylation by acetylcholine receptors. Eur J Pharmacol 393:255-263.
54. Hory-Lee F, Frank E. 1995. The nicotinic blocking agents d-tubocurare and alpha-bungarotoxin save motoneurons from naturally occurring death in the absence of neuromuscular blockade. J Neurosci 15:6453-6460.
55. Janson AM, Fuxe K, Goldstein M. 1992. Differential effects of acute and chronic nicotine treatment on MPTP-(1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) induced degeneration of nigrostriatal dopamine neurons in the black mouse. Clin Invest 70:232-238.
56. Janson AM, Fuxe K, Sundstrom E, Agnati LF, Goldstein M. 1988. Chronic nicotine treatment partly protects against the 1-methyl-4-phenyl-2,3,6-tetrahydropyridine-induced degeneration of nigrostriatal dopamine neurons in the black mouse. Acta Physiol Scand 132:589-591.
57. Janson AM, Hedlund PB, Fuxe K, von Euler G. 1994. Chronic nicotine treatment counteracts dopamine D2 receptor upregulation induced by a partial meso-diencephalic hemitransection in the rat. Brain Res 655:25-32.
58. Janson AM, Moller A. 1993. Chronic nicotine treatment counteracts nigral cell loss induced by a partial mesodiencephalic hemitransection: An analysis of the total number and mean volume of neurons and glia in substantia nigra of the male rat. Neuroscience 57:931-941.
59. Jeyarasasingam G, Tompkins L, Quik M. 2002. Stimulation of non-alpha7 nicotinic receptors partially protects dopaminergic neurons from 1-methyl-4-phenylpyridinium-induced toxicity in culture. Neuroscience 109:275-285.
60. Jonnala RR, Terry Jr AV, Buccafusco JJ. 2002. Nicotine increases the expression of high affinity nerve growth factor receptors in both in vitro and in vivo. Life Sci 70:1543-1554.
61. Kagitani F, Uchida S, Hotta H, Sato A. 2000. Effects of nicotine on blood flow and delayed neuronal death following intermittent transient ischemia in rat hippocampus. Jpn J Physiol 50:585-595.
62. Kaneko S, Maeda T, Kume T, Kochiyama H, Akaike A, Shimohama S, Kimura J. 1997. Nicotine protects cultured cortical neurons against glutamate-induced cytotoxicity via alpha7-neuronal receptors and neuronal CNS receptors. Brain Res 765:135-140.
63. Kasa P, Rakonczay Z, Gulya K. 1997. The cholinergic system in Alzheimer's disease. Prog Neurobiol 52:511-535.
64. Kihara T, Shimohama S, Sawada H, Honda K, Nakamizo T, Shibasaki H, Kume T, Akaike A. 2001. Alpha 7 nicotinic receptor transduces signals to phosphatidylinositol 3-kinase to block A beta-amyloid-induced neurotoxicity. J Biol Chem 276:13541-13546.
65. Kihara T, Shimohama S, Sawada H, Kimura J, Kume T, Kochiyama H, Maeda T, Akaike A. 1997. Nicotinic receptor stimulation protects neurons against beta-amyloid toxicity. Ann Neurol 42:159-163.
66. Kihara T, Shimohama S, Urushitani M, Sawada H, Kimura J, Kume T, Maeda T, Akaike A. 1998. Stimulation of alpha-4-beta-2 nicotinic acetylcholine receptors inhibits beta-amyloid toxicity. Brain Res 792:331-334.
67. Kim HC, Jhoo WK, Ko KH, Kim WK, Bing G, Kwon MS, Shin EJ, Suh JH, Lee YG, Lee DW. 2000. Prolonged exposure to cigarette smoke blocks the neurotoxicity induced by kainic acid in rats. Life Sci 66:317-326.
68. Kim SH, Kim YK, Jeong SJ, Haass C, Kim YH, Suh YH. 1997. Enhanced release of secreted form of Alzheimer's amyloid precursor protein from PC12 cells by nicotine. Mol Pharmacol 52:430-436.
69. Laudenbach V, Medja F, Zoli M, Rossi F, Evrard P, Changeux J, Gressens P. 2002. Selective activation of central subtypes of the nicotinic acetylcholine receptor has opposite effects on neonatal excitotoxic brain injuries. FASEB J, to appear.
70. Levin ED, Torry D. 1996. Acute and chronic nicotine effects on working memory in aged rats. Psychopharmacology 123:88-97.
71. Li MD, Kane JK, Matta SG, Blaner WS, Sharp BM. 2000. Nicotine enhances the biosynthesis and secretion of transthyretin from the choroid plexus in rats: Implications for beta-amyloid formation. J Neurosci 20:1318-1323.
72. Liu Q, Kawai H, Berg DK. 2001. Beta -amyloid peptide blocks the response of alpha 7-containing nicotinic receptors on hippocampal neurons. Proc Natl Acad Sci USA 98:4734-4739.
73. Maggio R, Riva M, Vaglini F, Fornai F, Molteni R, Armogida M, Racagni G, Corsini GU. 1998. Nicotine preents experimental parkinsonism in rodents and induces striatal increase of neurotrophic factors. J Neurochem 71:2439-2446.
74. Maggio R, Riva M, Vaglini F, Fornai F, Racagni G, Corsini GU. 1997. Striatal increase of neurotrophic factors as a mechanism of nicotine protection in experimental parkinsonism. J Neural Transm 104:1113-1123.
75. Marchi M, Risso F, Viola C, Cavazzani P, Raiteri M. 2002. Direct evidence that release-stimulating alpha7* nicotinic cholinergic receptors are localized on human and rat brain glutamatergic axon terminals. J Neurochem 80:1071-1078.
76. Marin P, Maus M, Desagher S, Glowinski J, Premont J. 1994. Nicotine protects cultured striatal neurones against N-methyl-D-aspartate receptor-mediated neurotoxicity. NeuroReport 5:1977-1980.
77. Marutle A, Warpman U, Bogdanovic N, Nordberg A. 1998. Regional distribution of subtypes of nicotinic receptors in human brain and effect of aging studied by (±)-[3H]epibatidine. Brain Res 801:143-149.
78. Maurice T, Lockhart BP, Privat A. 1996. Amnesia induced in mice by centrally administered beta-amyloid peptides involves cholinergic dysfunction. Brain Res 706:181-193.
79. Meguro K, Yamaguchi S, Arai H, Nakagawa T, Doi C, Yamada M, Ikarashi Y, Maruyama Y, Sasaki H. 1994. Nicotine improves cognitive disturbance in senescence-accelerated mice. Pharmacol Biochem Behav 49:769-772.
80. Messi ML, Renganathan M, Grigorenko E, Delbono O. 1997. Activation of alpha7 nicotinic acetylcholine receptor promotes survival of spinal cord motoneurons. FEBS Lett 411:32-38.
81. Meyer EL, Gahring LC, Rogers SW. 2002. Nicotine preconditioning antagonizes activity-dependent caspase proteolysis of a glutamate receptor. J Biol Chem 277:10869-10875.
82. Meyer EM, King MA, Meyers C. 1998a. Neuroprotective effects of 2,4-dimethoxybenzylidene anabaseine (DMXB) and tetrahydroaminoacridine (THA) in neocortices of nucleus basalis lesioned rats. Brain Res 786:252-254.
83. Meyer EM, Tay ET, Zoltewicz JA, Meyers C, King MA, Papke RL, De Fiebre CM. 1998b. Neuroprotective and memory-related actions of novel alpha-7 nicotinic agents with different mixed agonist/antagonist properties. J Pharmacol Exp Ther 284:1026-1032.
84. Minana MD, Montoliu C, Llansola M, Grisolia S, Felipo V. 1998. Nicotine prevents glutamate-induced proteolysis of the microtubule-associated protein MAP-2 and glutamate neurotoxicity in primary cultures of cerebellar neurons. Neuropharmacology 37:847-857.
85. Monteggia LM, Arneric SP, Giordano T. 1994. Nicotine effects on the regulation of amyloid precursor protein splicing, neurotrophin and glucose transporter RNA levels in aged rats. International J Dev Neurosci 12:133-141.
86. Muneoka K, Nakatsu T, Fuji J, Ogawa T, Takigawa M. 1999. Prenatal administration of nicotine results in dopaminergic alterations in the neocortex. Neurotoxicol Teratol 21:603-609.
87. Nagele RG, D'Andrea MR, Anderson WJ, Wang HY. 2002. Intracellular accumulation of beta-amyloid(1-42) in neurons is facilitated by the alpha7 nicotinic acetylcholine receptor in Alzheimer's disease. Neuroscience 110:199-211.
88. Nakayama H, Numakawa T, Ikeuchi T, Hatanaka H. 2001. Nicotine-induced phosphorylation of extracellular signal-regulated protein kinase and CREB in PC12 cells. J Neurochem 79:489-498.
89. Nanri M, Kasahara N, Yamamoto J, Miyake H, Watanabe H. 1997. GTS-21, a nicotinic agonist, protects against neocortical neuronal cell loss induced by the nucleus basalis magnocellularis lesion in rats. Jpn J Pharmacol 74:285-289.
90. Nanri M, Miyake H, Murakami Y, Matsumoto K, Watanabe H. 1998. GTS-21, a nicotinic agonist, attenuates multiple infarctions and cognitive deficit caused by permanent occlusion of bilateral common carotid arteries in rats. Jpn J Pharmacol 78:463-469.
91. Nordberg A. 1992. Neuroreceptor changes in Alzheimer disease. Cerebrovasc Brain Metab Rev 4:303-328.
92. Nordberg A, Lilja A, Lundqvist H, Hartvig P, Amberla K, Viitanen M, Warpman U, Johansson M, Hellstromlindahl E, Bjurling P, Fasth KJ, Langstrom B, Winblad B. 1992. Tacrine restores cholinergic nicotinic receptors and glucose metabolism in Alzheimer patients as visualized by Positron Emission Tomography. Neurobiol Aging 13:747-758.
93. Nordberg A, Lundqvist H, Hartvig P, Andersson J, Johansson M, Hellstrom-Lindahi E, Langstrom B. 1997. Imaging of nicotinic and muscarinic receptors in Alzheimer's disease: Effect of tacrine treatment. Dement Geriatr Cogn Disord 8:78-84.
94. Nordberg A, Hellström-Lindahl E, Lee M, Johnson M, Mousavi M, Hall R, Perry E, Bednar I, Court J. 2002. Chronic nicotine treatment reduces beta-amyloidosis in the brain of a mouse model of Alzheimer's disease (APPsw). J Neurochem 81:655-658.
95. Okamoto M, Kita T, Okuda H, Tanaka T, Nakashima T. 1994. Effects of aging on acute toxicity of nicotine in rats. Pharmacol Toxicol 75:1-6.
96. O'Neill AB, Morgan SJ, Brioni JD. 1998. Histological and behavioral protection by (-)-nicotine against quinolinic acid-induced neurodegeneration in the hippocampus. Neurobiol Learn Mem 69:46-64.
97. Onoda N, Nehmi A, Weiner D, Mujumdar S, Christen R, Los G. 2001. Nicotine affects the signaling of the death pathway, reducing the response of head and neck cancer cell lines to DNA damaging agents. Head Neck 23:860-870.
98. Owman C, Fuxe K, Janson AM, Kahrstrom J. 1989. Studies of protective actions of nicotine on neuronal and vascular functions in the brain of rats: Comparison between sympathetic noradrenergic and mesostriatal dopaminergic fiber systems, and the effect of a dopamine agonist. Prog Brain Res 79:267-276.
99. Parain K, Marchand V, Dumery B, Hirsch E. 2001. Nicotine, but not cotinine, partially protects dopaminergic neurons against MPTP-induced degeneration in mice. Brain Res 890:347-350.
100. Perry E, Martin-Ruiz C, Lee M, Griffiths M, Johnson M, Piggott M, Haroutunian V, Buxbaum JD, Nasland J, Davis K, Gotti C, Clementi F, Tzartos S, Cohen O, Soreq H, Jaros E, Perry R, Ballard C, McKeith I, Court J. 2000. Nicotinic receptor subtypes in human brain ageing, Alzheimer and Lewy body diseases. Eur J Pharmacol 393:215-222.
101. Perry EK, Morris CM, Court JA, Cheng A, Fairbairn AF, McKeith IG, Irving D, Brown A, Perry RH. 1995. Alteration in nicotine binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's disease: Possible index of early neuropathology. Neuroscience 64:385-395.
102. Pettit DL, Shao Z, Yakel JL. 2001. Beta-amyloid 1-42 peptide directly modulates nicotinic receptors in the rat hippocampal slice. J Neurosci 21:1-5.
103. Picciotto MR, Zoli M, Léna C, Bessis A, Lallemand Y, Le Novère N, Vincent P, Merlo Pich E, Brulet P, Changeux J-P. 1995. Abnormal avoidance learning in mice lacking functional high-affinity nicotine receptor in the brain. Nature 374:65-67.
104. Prendergast MA, Harris BR, Mayer S, Holley RC, Hauser KF, Littleton JM. 2001a. Chronic nicotine exposure reduces N-methyl-D-aspartate receptor-mediated damage in the hippocampus without altering calcium accumulation or extrusion: Evidence of calbindin-D28K overexpression. Neuroscience 102:75-85.
105. Prendergast MA, Harris BR, Mayer S, Holley RC, Pauly JR, Littleton JM. 2001b. Nicotine exposure reduces N-methyl-D-aspartate toxicity in the hippocampus: Relation to distribution of the α7 nicotinic acetylcholine receptor subunit. Med Sci Monitor 7:1153-1160.
106. Prendergast MA, Harris BR, Mayer S, Littleton JM. 2000. Chronic, but not acute, nicotine exposure attenuates ethanol withdrawal-induced hippocampal damage in vitro. Alcoholism:Clin Exp Res 24:1583-1592.
107. Quik M, Jeyarasasingam G. 2000. Nicotinic receptors and Parkinson's disease. Eur J Pharmacol 393:223-230.
108. Quik M, Di Monte DA. 2001. Nicotine administration reduces striatal MMP+ levels in mice. Brain Res 917:219-224.
109. Reid RT, Sabbagh MN, Corey-Bloom J, Tiraboschi P, Thal LJ. 2000. Nicotinic receptor losses in dementia with Lewy bodies: Comparisons with Alzheimer's disease. Neurobiol Aging 21:741-746.
110. Renshaw GM, Dyson SE. 1995. Alpha-BTX lowers neuronal metabolism during the arrest of motoneurone apoptosis. NeuroReport 6:284-288.
111. Robbins TW, McAlonan G, Muir JL, Everitt BJ. 1997. Cognitive enhancers in theory and practice: Studies of the cholinergic hypothesis of cognitive deficits in Alzheimer's disease. Behav Brain Res 83:15-23.
112. Roberson MR, Harrell LE. 1997. Cholinergic activity and amyloid precursor protein metabolism. Brain Res Rev 25:50-69.
113. Rogers SW, Gahring LC, Collins AC, Marks M. 1998. Age-related changes in neuronal nicotinic acetylcholine receptor subunit alpha4 expression are modified by longterm nicotine administration. J Neurosci 18:4825-4832.
114. Roy TS, Sabherwal U. 1994. Effects of prenatal nicotine exposure on the morphogenesis of somatosensory cortex. Neurotoxicol Teratol 16:411-421.
115. Rusted JM, Newhouse PA, Levin ED. 2000. Nicotinic treatment for degenerative neuropsychiatric disorders such as Alzheimer's disease and Parkinson's disease. Beh Brain Res 113:121-129.
116. Ryan RE, Ross SA, Drago J, Loiacono RE. 2001. Dose-related neuroprotective effects of chronic nicotine in 6-hydroxydopamine treated rats, and loss of neuroprotection in alpha4 nicotinic receptor subunit knockout mice. Br J Pharmacol 132:1650-1656.
117. Salomon AR, Marcinowski KJ, Friedland RP, Zagorski MG. 1996. Nicotine inhibits amyloid formation by the beta-peptide. Biochemistry 35:13568-13578.
118. Schroder H, Giacobini E, Struble RG, Zilles K, Maelicke A. 1991. Nicotinic cholinoceptive neurons of the frontal cortex are reduced in Alzheimer's disease. Neurobiol Aging 12:259-262.
119. Schulz DW, Kuchel GA, Zigmond RE. 1993. Decline in response to nicotine in aged rat striatum: Correlation with a decrease in a subpopulation of nicotinic receptors. J Neurochem 61:2225-2232.
120. Selkoe DJ. 1994. Cell biology of the amyloid beta-protein precursor and the mechanism of Alzheimer's disease. Annu Rev Cell Biol 10:373-403.
121. Semba J, Miyoshi R, Kito S. 1996. Nicotine protects against the dexamethasone potentiation of kainic acid-induced neurotoxicity in cultured hippocampal neurons. Brain Res 735:335-338.
122. Sershen H, Mason MF, Reith ME, Hashim A, Lajtha A. 1986. Effect of nicotine and amphetamine on the neurotoxicity of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mice. Neuropharmacol 25:1231-1234.
123. Shimohama S, Greenwald DL, Shafron DH, Akaika A, Maeda T, Kaneko S, Kimura J, Simpkins CE, Day AL, Meyer EM. 1998. Nicotinic alpha 7 receptors protect against glutamate neurotoxicity and neuronal ischemic damage. Brain Res 779:359-363.
124. Sjak-Shie NN, Meyer EM. 1993. Effects of chronic nicotine and pilocarpine administration on neocortical neuronal density and [3H]GABA uptake in nucleus basalis lesioned rats. Brain Res 624:295-298.
125. Smith TD, Gallagher M, Leslie FM. 1995. Cholinergic binding sites in rat brain: Analysis by age and cognitive status. Neurobiol Aging 16:161-173.
126. Socci DJ, Arendash GW. 1996. Chronic nicotine treatment prevents neuronal loss in neocortex resulting from nucleus basalis lesions in young adult and aged rats. Mol Chem Neuropathol 27:285-305.
127. Socci DJ, Sanberg PR, Arendash GW. 1995. Nicotine enhances Morris water maze performance of young and aged rats. Neurobiol Aging 16:857-860.
128. Strahlendorf JC, Acosta S, Miles R, Strahlendorf HK. 2001. Choline blocks AMPA-induced dark cell degeneration of Purkinje neurons: Potential role of the alpha7 nicotinic receptor. Brain Res 901:71-78.
129. Sugaya K, Giacobini E, Chiappinelli VA. 1990. Nicotinic acetylcholine receptor subtypes in human frontal cortex: Changes in Alzheimer's disease. J Neurosci Res 27:349-359.
130. Terzano S, Court JA, Fornasari D, Griffiths M, Spurden DP, Lloyd S, Perry RH, Perry EK, Clementi F. 1998. Expression of the alpha 3 nicotinic receptor subunit mRNA in aging and Alzheimer's disease. Mol Brain Res 63:72-78.
131. Toborek M, Garrido R, Malecki A, Kaiser S, Mattson MP, Hennig B, Young B. 2000. Nicotine attenuates arachidonic acid-induced overexpression of nitric oxide synthase in cultured spinal cord neurons. Exp Neurol 161:609-620.
132. Tohgi H, Utsugisawa K, Yoshimura M, Nagane Y, Mihara M. 1998a. Age-related changes in nicotinic acetylcholine receptor subunits alpha4 and beta2 messenger RNA expression in postmortem human frontal cortex and hippocampus. Neurosci Lett 245:139-142.
133. Tohgi H, Utsugisawa K, Yoshimura M, Nagane Y, Mihara M. 1998b. Alterations with aging and ischemia in nicotinic acetylcholine receptor subunits alpha4 and beta2 messenger RNA expression in postmortem human putamen. Implications for susceptibility to parkinsonism. Brain Res 791:186-190.
134. Trauth JA, Seidler FJ, Slotkin TA. 2000. An animal model of adolescent nicotine exposure: Effects on gene expression and macromolecular constituents in rat brain regions. Brain Res 867:29-39.
135. Uchida S, Kagitani F, Nakayama H, Sato A. 1997. Effect of stimulation of nicotinic cholinergic receptors on cortical cerebral blood flow and changes in the effect during aging in anesthetized rats. Neurosci Lett 228:203-206.
136. Utsugisawa K, Nagane Y, Tohgi H, Yoshimura M, Ohba H, Genda Y. 1999. Changes with aging and ischemia in nicotinic acetylcholine receptor subunit alpha7 mRNA expression in postmortem human frontal cortex and putamen. Neurosci Lett 270:145-148.
137. Wang HY, Lee DH, D'Andrea MR, Peterson PA, Shank RP, Reitz AB. 2000. Beta-amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology. J Biol Chem 275:5626-5632.
138. Wang L, Kittaka M, Sun N, Schreiber SS, Zlokovic BV. 1997. Chronic nicotine treatment enhances focal ischemic brain injury and depletes free pool of brain microvascular tissue plasminogen activator in rats. J Cer Blood Flow Metabol 17:136-146.
139. Warpman U, Nordberg A. 1995. Epibatidine and ABT 418 reveal selective losses of alpha 4 beta 2 nicotinic receptors in Alzheimer brains. NeuroReport 6:2419-2423.
140. Zamani MR, Allen YS, Owen GP, Gray JA. 1997. Nicotine modulates the neurotoxic effect of beta-amyloid protein(25-35) in hippocampal cultures. NeuroReport 8:513-517.
141. Zhang X, Wahlstrom G, Nordberg A. 1990. Influence of development and aging on nicotinic receptor subtypes in rodent brain. Int J Dev Neurosci 8:715-721.
142. Zilles K, Becker CM, Schleicher A. 1982. Nicotinic ACh receptor blockade and spontaneous nerve cell death in various brain regions. Bibliotheca Anatomica 23:40-55.
143. Zoli M, Léna C, Picciotto MR, Changeux J-P. 1998. Identification of four classes of brain nicotinic receptors using β2-mutant mice. J Neurosci 18:4461-4472.
144. Zoli M, Picciotto MR, Ferrari R, Cocchi D, Changeux J-P. 1999. Increased neurodegeneration during aging in mice lacking high-affinity nicotine receptors. EMBO J 18:1235-1244.